330 related articles for article (PubMed ID: 18090508)
1. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
2. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report.
Mukaddes NM; Abali O; Kaynak N
Psychiatry Clin Neurosci; 2003 Aug; 57(4):405-8. PubMed ID: 12839522
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
4. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.
Dougherty DD; Jameson M; Deckersbach T; Loh R; Thompson-Hollands J; Jenike M; Keuthen NJ
Int Clin Psychopharmacol; 2009 Nov; 24(6):306-11. PubMed ID: 19730388
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
6. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Tollefson GD; Birkett M; Koran L; Genduso L
J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy assessment of fluoxetine treatment of outpatients with obsessive-compulsive disorder: a preliminary report].
Wandzel L
Psychiatr Pol; 1997; 31(4):429-35. PubMed ID: 9527686
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.
Greenberg WM; Benedict MM; Doerfer J; Perrin M; Panek L; Cleveland WL; Javitt DC
J Psychiatr Res; 2009 Mar; 43(6):664-70. PubMed ID: 19046587
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with citalopram in the treatment of adolescent OCD.
Thomsen PH; Ebbesen C; Persson C
J Am Acad Child Adolesc Psychiatry; 2001 Aug; 40(8):895-902. PubMed ID: 11501688
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
Stein DJ; Andersen EW; Tonnoir B; Fineberg N
Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626
[TBL] [Abstract][Full Text] [Related]
12. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram in seasonal affective disorder: results of an open trial.
Pjrek E; Winkler D; Stastny J; Praschak-Rieder N; Willeit M; Kasper S
Pharmacopsychiatry; 2007 Jan; 40(1):20-4. PubMed ID: 17327956
[TBL] [Abstract][Full Text] [Related]
14. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Coric V; Taskiran S; Pittenger C; Wasylink S; Mathalon DH; Valentine G; Saksa J; Wu YT; Gueorguieva R; Sanacora G; Malison RT; Krystal JH
Biol Psychiatry; 2005 Sep; 58(5):424-8. PubMed ID: 15993857
[TBL] [Abstract][Full Text] [Related]
15. Capsulotomy for obsessive-compulsive disorder: long-term follow-up of 25 patients.
Rück C; Karlsson A; Steele JD; Edman G; Meyerson BA; Ericson K; Nyman H; Asberg M; Svanborg P
Arch Gen Psychiatry; 2008 Aug; 65(8):914-21. PubMed ID: 18678796
[TBL] [Abstract][Full Text] [Related]
16. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
17. Course of obsessive-compulsive disorder during early postpartum period: a prospective analysis of 16 cases.
Uguz F; Gezginc K; Zeytinci IE; Karatayli S; Askin R; Guler O; Sahin FK; Emul HM; Ozbulut O; Gecici O
Compr Psychiatry; 2007; 48(6):558-61. PubMed ID: 17954142
[TBL] [Abstract][Full Text] [Related]
18. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard G; Goodman W; Greist J; Jenike M; Rasmussen S; White K; Hackett E; Gaffney M; Bick PA
Psychopharmacol Bull; 1990; 26(3):279-84. PubMed ID: 2274626
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
Schmitt L; Tonnoir B; Arbus C
Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
[TBL] [Abstract][Full Text] [Related]
20. [Prospective follow-up over a 12 month period of a cohort of 155 patients with obsessive-compulsive disorder: phase III National DRT-TOC Study].
Hantouche EG; Bouhassira M; Lancrenon S
Encephale; 2000; 26(6):73-83. PubMed ID: 11217541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
